Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 769-774

  Mutnick, Alan H ^a,b,f   Enne, Victoria ^c   Jones, Ronald N ^d,e  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d JONES Group   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f The JONES Group   (United States)

Author keywords

Linezolid; Resistance; Surveillance

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN G; POSIZOLID; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD FLOW; CHILD; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EPIDEMIOLOGICAL DATA; FEMALE; GRAM POSITIVE COCCI; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MULTICENTER STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; STRAIN IDENTIFICATION; STREPTOCOCCUS ORALIS; UNITED STATES; URINARY TRACT INFECTION;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES;

EID: 0037561936     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C437     Document Type: Article

References (25)

1. Nosocomial enterococci resistant to vancomycin - United States. 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
2. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:65-73.
3. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar W, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid (letter). Lancet 2001;357:1179.
4. Tsiodras A, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
5. Zurenko GE, Todd WM, Hafkin B, Myers B, Kauffman C, Bock J. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid (abstract 848). In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sept 17-20, 2000:118.
6. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002;42:137-9.
7. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezoid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346: 867-9.
8. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson L, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:2154-6.
9. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. The SENTRY Participants Group Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western-Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S114-32.
10. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S81-93.
11. Jones RN, Pfaller MA. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J Clin Microbiol 2000;38:4298-9.
12. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY Surveillance Programme. J Antimicrob Chemother 1999;43: 783-92.
13. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000b.
14. Performance standard for antimicrobial susceptibility testing. Document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
15. Performance standards for antimicrobial disk susceptibility tests. Document M2-A7. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
16. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46:3334-6.
17. Errors in health care: a leading cause of death and injury. In: Kohn LT, Corrigan JM, Donaldson MS, eds. Too err is human: building a safer health system. Institute of Medicine Report. Chapter 2, errors in health care: a leading cause of death and injury. Washington, DC: National Academy Press, 1999:22-41. www.nap.edu/html/to_err_is_human/ (accessed 2003 Jan 16).
18. Haley RW, Culver DH, White JW, Morgan WM, Emori TG. The nationwide nosocomial infection rate: a new need for vital statistics. Am J Epidemiol 1985;121:159-67.
19. Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in U.S. hospitals. Am J Epidemiol 1985; 121:182-205.
20. Martone WJ, Jarvis WR, Culver DH, Haley RW. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman PS, eds. Hospital infections. Boston: Little, Brown, and Company, 1992: 577-96.
21. Kuehm SL, Doyle MJ. Medication errors: 1977-1988. Experience in medical malpractice claims. N J Med 1990;87:27-34.
22. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6. DOI 10.1345/aph.1A333
23. ASM Task Force, 1994: Discussion paper: "a proposed framework for evaluating and assuring the human safety of the microbial effects of antimicrobial new animal drugs intended for use in food-producing animals." Food and Drug Administration (FDA), Department of Health and Human Services (HHS) Docket No. 98D-1146. www.asmusa.org/pasrc/fdaframework.htm (accessed 2003 Apr 9).
24. EU Conference, 2001; Visby, Sweden; June 13-15, 2001: progress report on antimicrobial resistance, www.fedesa.be/Antibio/Visby/microbialthreat. pdf (accessed 2003 Apr 9).
25. WHO global strategy for containment of antimicrobial resistance, 2001. www.who.int/emcdocuments/antimicrobial_resistance/docs/EGlobal_Strat. pdf (accessed 2003 Apr 9).